REXAHN PHARMACEUTICALS, INC. | Business Contracts

Non-Employee Director Compensation Policy (Filed With SEC on August 12, 2022)

Third Lease Amendment, dated as of September 9, 2021, by and between the Company and Duke & Duke (Filed With SEC on November 12, 2021)

License Agreement dated June 16, 2021 (Filed With SEC on June 23, 2021)

Form of Warrant to purchase shares of common stock (Filed With SEC on June 7, 2021)

Placement Agency Agreement, dated as of June 4, 2021, by and between Ocuphire Pharma, Inc. and A.G.P./Alliance Global Partners (Filed With SEC on June 7, 2021)

Form of Lock-Up Agreement, by and between the Company, OcuSub, Inc. and certain stockholders (Filed With SEC on March 11, 2021)

Agreement and Plan of Merger, dated as of June 17, 2020, by and among the Company, Merger Sub and Ocuphire (Filed With SEC on August 14, 2020)

Consulting Agreement between the Registrant and Jay Pepose dated April 8, 2022 (Filed With SEC on May 13, 2022)

Form of Securities Purchase Agreement, dated as of June 4, 2021, by and among Ocuphire Pharma, Inc. and the purchasers identified on the signature pages thereto (Filed With SEC on June 7, 2021)

Placement Agency Agreement, dated as of June 4, 2021, by and between Ocuphire Pharma, Inc. and A.G.P./Alliance Global Partners (Filed With SEC on June 4, 2021)

Form of Warrant to purchase shares of common stock (Filed With SEC on June 4, 2021)

Form of Securities Purchase Agreement, dated as of June 4, 2021, by and among Ocuphire Pharma, Inc. and the purchasers identified on the signature pages thereto (Filed With SEC on June 4, 2021)

Ocuphire Pharma, Inc. 2020 Inducement Plan (Filed With SEC on March 11, 2021)

Employment Agreement dated November 11, 2020, by and between the Company and Amy Rabourn (Filed With SEC on March 11, 2021)

Second Lease Amendment, dated as of November 17, 2020, by and between the Company and Duke & Duke (Filed With SEC on March 11, 2021)

Capital on Demand Sales Agreement, dated March 11, 2021 between Ocuphire Pharma, Inc. and JonesTrading Institutional Services LLC (Filed With SEC on March 11, 2021)

Description of Securities (Filed With SEC on March 11, 2021)

Form of Waiver Agreement, dated as of February 3, 2021, by and between Ocuphire Pharma, Inc. and the Holder(s) (Filed With SEC on February 4, 2021)

Form of Indemnity Agreement between the Company and each of its directors and executive officers (Filed With SEC on November 6, 2020)

Contingent Value Rights Agreement, dated as of November 5, 2020, by and among the Company, Shareholder Representative Services LLC and the Olde Monmouth Stock Transfer Co., Inc (Filed With SEC on November 6, 2020)

Non-Employee Director Compensation Policy of the Company (Filed With SEC on November 6, 2020)

Warrant Exchange Agreement, dated September 10, 2020, by and between Rexahn Pharmaceuticals, Inc. and Empery Tax Efficient II, LP (Filed With SEC on September 11, 2020)

Warrant Exchange Agreement, dated September 10, 2020, by and between Rexahn Pharmaceuticals, Inc. and Empery Tax Efficient, LP (Filed With SEC on September 11, 2020)

Warrant Exchange Agreement, dated September 10, 2020, by and between Rexahn Pharmaceuticals, Inc. and Empery Asset Master, Ltd (Filed With SEC on September 11, 2020)

Warrant Exchange Agreement, dated September 1, 2020, by and between Rexahn Pharmaceuticals, Inc. and Anson Investments Master Fund LP (Filed With SEC on September 2, 2020)

Warrant Exchange Agreement, dated July 31, 2020, by and between Rexahn Pharmaceuticals, Inc. and Armistice Capital Master Fund Ltd (Filed With SEC on August 3, 2020)

Lease Agreement, dated as of May 19, 2019, by and between Ocuphire Pharma, Inc. and Duke & Duke, LP (Filed With SEC on July 6, 2020)

Employment Agreement, dated as of October 1, 2018, between Ocuphire Pharma, Inc. and Bernhard Hoffmann (Filed With SEC on July 6, 2020)

Stockholders Agreement, dated as of April 10, 2018, among Ocuphire Pharma, Inc. and Stockholders as defined therein (Filed With SEC on July 6, 2020)

Employment Agreement, dated as of October 1, 2018, between Ocuphire Pharma, Inc. and Mina Sooch (Filed With SEC on July 6, 2020)

First Amendment to Lease Agreement, dated as of October 29, 2019, by and between Ocuphire Pharma, Inc. and Duke & Duke, LP (Filed With SEC on July 6, 2020)

Amended and Restated Employment Agreement by and among Ocuphire Pharma, Inc. and Mina Sooch, to be effective as of the Closing (Filed With SEC on July 6, 2020)

Amended and Restated Employment Agreement by and among Ocuphire Pharma, Inc. and Bernhard Hoffmann, to be effective as of the Closing (Filed With SEC on July 6, 2020)

Form of Indemnification Agreement (Filed With SEC on July 6, 2020)

Sublicense Agreement, dated as of January 21, 2020, by and between Ocuphire Pharma, Inc. and Apexian Pharmaceuticals, Inc (Filed With SEC on July 6, 2020)

Note Conversion Agreement, dated as of June 8, 2020, by and among Ocuphire Pharma, Inc. and each of the purchasers party to the Amended and Restated Mezz Note Purchase Agreement (Filed With SEC on July 6, 2020)

First Amendment to Amended and Restated Mezz Note Purchase Agreement, dated as of November 20, 2019, by and among Ocuphire Pharma, Inc. and each of the purchasers party to the... (Filed With SEC on July 6, 2020)

Amended and Restated Mezz Note Purchase Agreement, dated as of January 22, 2019, by and among Ocuphire Pharma, Inc. and each of the purchasers set forth therein (Filed With SEC on July 6, 2020)

Form of Option Agreement issuable under the Ocuphire Pharma, Inc. 2018 Equity Incentive Plan (Filed With SEC on July 6, 2020)

First Amendment to Sublicense Agreement, dated as of June 4, 2020, by and between Apexian Pharmaceuticals, Inc. and Ocuphire Pharma, Inc (Filed With SEC on July 6, 2020)

Ocuphire Pharma, Inc. 2018 Equity Incentive Plan, dated as of April 9, 2019 (Filed With SEC on July 6, 2020)

First Amendment to 2018 Equity Incentive Plan, dated as of December 23, 2019 (Filed With SEC on July 6, 2020)

Form of Leak-Out Agreement, by and between Rexahn and the investors party thereto (Filed With SEC on July 1, 2020)

Form of Financing Lock-Up Agreement, by and among Rexahn, Ocuphire, and the investors party thereto (Filed With SEC on July 1, 2020)

Amended and Restated Securities Purchase Agreement, dated as of June 29, 2020, by and among Rexahn, Ocuphire and the investors party thereto (Filed With SEC on July 1, 2020)

Form of Series A/B Warrants (Filed With SEC on July 1, 2020)

First Amendment to Agreement and Plan of Merger and Reorganization, dated as of June 29, 2020, by and among Rexahn, Merger Sub and Ocuphire (Filed With SEC on July 1, 2020)

Registration Rights Agreement, dated June 17, 2020, by and among Rexahn and certain investors named therein (Filed With SEC on June 19, 2020)

Form of Leak-Out Agreement, by and between Rexahn and the investors party thereto (Filed With SEC on June 19, 2020)

Form of Financing Lock-Up Agreement, by and among Rexahn, Ocuphire, and the investors party thereto (Filed With SEC on June 19, 2020)

Securities Purchase Agreement, dated as of June 17, 2020, by and among Rexahn, Ocuphire and the investors party thereto (Filed With SEC on June 19, 2020)

Form of Lock-Up Agreement, by and among Rexahn, Ocuphire and certain stockholders of Rexahn and Ocuphire (Filed With SEC on June 19, 2020)

Form of Ocuphire Voting Agreement, by and among Ocuphire, Rexahn and certain stockholders of Ocuphire (Filed With SEC on June 19, 2020)

Form of CVR Agreement, by and among Rexahn, the CVR Representative, and the Rights Agent (Filed With SEC on June 19, 2020)

Form of Series A/B Warrants (Filed With SEC on June 19, 2020)

Agreement and Plan of Merger, dated as of June 17, 2020, by and among Rexahn, Merger Sub and Ocuphire (Filed With SEC on June 19, 2020)

Amendment No. 2 to Collaboration and License Agreement, dated as of March 10, 2020 between BioSense Global LLC and Rexahn Pharmaceuticals, Inc (Filed With SEC on May 7, 2020)

Description of Common Stock (Filed With SEC on February 21, 2020)

Amendment No. 1 to Collaboration and License Agreement (Filed With SEC on August 29, 2019)

Collaboration and License Agreement, dated as of February 25, 2019, between BioSense Global LLC and Rexahn Pharmaceuticals, Inc (Filed With SEC on August 7, 2019)

Sixth Amendment to Lease Agreement, dated as of March 18, 2019, by and between the registrant and SG Plaza Holdings, LLC (Filed With SEC on May 10, 2019)

Form of Restricted Stock Unit Agreement under the Rexahn Pharmaceuticals, Inc. 2013 Stock Option Plan (Filed With SEC on March 7, 2019)

Underwriting Agreement, dated January 23, 2019, by and between Rexahn Pharmaceuticals, Inc. and Oppenheimer & Co. Inc (Filed With SEC on January 25, 2019)

Form of Warrant (Filed With SEC on January 25, 2019)

REXAHN PHARMACEUTICALS, INC. (64)